tbuckley/cabot-search huggingface dataset:
Improved survival in patients with lung only recurrence after surgical resection of pancreatic ductal adenocarcinoma.
Authors: Michael S. May, Alissa Michel, Tristan Lee, Winston Wong, Jacob K.R. Jamison, David Manrique, Samuel M Pan, Jianhua Hu, Rachael A Safyan, Alexander Raufi, Michael Kluger, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji
Journal: Journal of Clinical Oncology (2022)

608 Background: Recurrence rates after resection of pancreatic ductal adenocarcinoma (PDA) can be up to 80%. Prior data suggests that initial site of recurrence influences prognosis. This study aims to compare survival of patients (pts) with resected PDA by initial site of recurrence. Methods: We retrospectively reviewed the demographics, treatments, recurrence and survival of 717 pts with PDA who underwent resection at Columbia University Irving Medical Center from 2011 to 2020 and were part of a tumor registry. Analyses were performed using Kaplan-Meier and paired T-tests. Results: Of 717 pts with resected PDA, 320 had confirmed recurrence. Median age at diagnosis was 67 years (yrs). Among pts with a single initial recurrence site, 36 recurred in lung, 97 in liver, 95 locally, and 23 in peritoneum. 58 pts had initial recurrence at 2 or more sites. Neoadjuvant treatment had been administered in 42%, 36%, 40%, 35%, and 22% of pts with lung, liver, local, peritoneal, and multiple sites at initial recurrence, respectively (p=0.21). Adjuvant treatment had been administered in 72%, 69%, 76%, 70%, and 72% of pts with lung, liver, local, peritoneal, and multiple sites at initial recurrence, respectively (p=0.88). Pts with initial lung recurrence had a significantly longer median overall survival (mOS), 4.39 yrs, compared to initial recurrence in the liver (1.98 yrs, p=0.02), peritoneum (2.19 yrs, p=0.0002), and at multiple sites (2.66 yrs, p=0.03). A significantly longer time from diagnosis to recurrence was observed in pts who had initial lung recurrence, compared to pts who had initial hepatic, peritoneal or multiple site recurrences. Pts with initial lung recurrence had a significantly longer time from first recurrence to death compared to pts with initial peritoneal recurrence. See Table for summary. Conclusions: Pts with resected PDA with initial pulmonary recurrence experience improved survival compared to those who recur at other distinct or multiple sites. The underlying pathways contributing to this improved survival need to be investigated further.[Table: see text]
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
Authors: Chunlei Zhang, Kexiang Yan, Qingchun Diao, Qing Guo, Hongzhong Jin, Sen Yang, Xiang Chen, Tiechi Lei, Jianhua Wu, Hong Yu, Min Zheng, Xinghua Gao, Rodney Sinclair, Yi Zhu, Qian Xu, Jinhua Xu
Journal: Journal of the American Academy of Dermatology (2022)
Altered atrial matrix metalloproteinase activity and calcium homeostasis in chronic rapid pacing-induced atrial failure Brian D. Hoit, Yasuchika Takeishi, Marjorie Gabel, Michael J. Cox, Darryl Kirkpatrick, Richard A. Walsh, Suresh C. Tyagi. University of Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH, University of Mississippi, Jackson, MS
Journal: Journal of the American College of Cardiology (2001)
THE INTERSTITIAL GLANDS OF THE TESTICLE.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FOUR " SLUM " CENTERS.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Books Received
Authors: Benjamin Sadock, Virginia Sadock, Martin Szuba, David Dinges, Jacqueline Kloss, Bill Fulford, Katherine Morris, John Sadler, Giovanni Stanghellini, Augusto Caraceni, Luigi Grassi, Jair Soares, Samuel Gershon
Journal: Psychotherapy and Psychosomatics (2004)

It is a collection of case histories of people involved in arts illustrating the interplay of neurosis and creativity, and provides a solid introduction into the primary issues related to emotional disorders and creativity.
Experts Discuss COVID-19—Variants and Vaccine Efficacy, Immunosuppressed Patients, and More
Authors: John Moore
Journal: JAMA (2021)

Domenico Luca Grieco, MD; Luca S. Menga, MD; Melania Cesarano, MD; Tommaso Rosà, MD; Savino Spadaro, MD, PhD; Maria Maddalena Bitondo, MD; Jonathan Montomoli, MD, PhD; Giulia Falò, MD; Tommaso Tonetti, MD; Salvatore L. Cutuli, MD; Gabriele Pintaudi, MD; Eloisa S. Tanzarella, MD; Edoardo Piervincenzi, MD; Filippo Bongiovanni, MD; Antonio M. Dell'Anna, MD; Luca Delle Cese, MD; Cecilia Berardi, MD; Simone Carelli, MD; Maria Grazia Bocci, MD; Luca Montini, MD; Giuseppe Bello, MD; Daniele Natalini, MD; Gennaro De Pascale, MD; Matteo Velardo, PhD; Carlo Alberto Volta, MD; V. Marco Ranieri, MD; Giorgio Conti, MD; Salvatore Maurizio Maggiore, MD, PhD; Massimo Antonelli, MD; COVID-ICU Gemelli Study Group; Gian Marco Anzellotti; Laura Cascarano; Francesca Ceccaroni; Paolo De Santis; Mariangela Di Muro; Miriana Durante; Nicoletta Filetici; Veronica Gennenzi; Antonio Gullì; Gianmarco Lombardi; Alessio Maccaglia; Riccardo Maviglia; Alessandro Mele; Giovanna Mercurio; Teresa Michi; Tony C. Morena; Martina Murdolo; Mariano Alberto Pennisi; Stefania Postorino; Antonella Potalivo; Francesca Pozzana; Carlotta Rubino; Martina Savino; Roberta Scarascia; Angela Scavone; Donatella Settanni; Serena Silva; Flavia Torrini; Joel Vargas; Carmelina Zaccone
Correction: <i>RAB37</i> Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma
Authors: Yingqin Li, Xiaojing Yang, Xiaojing Du, Yuan Lei, Qingmei He, Xiaohong Hong, Xinran Tang, Xin Wen, Panpan Zhang, Ying Sun, Jian Zhang, Yaqin Wang, Jun Ma, Na Liu
Journal: Clinical Cancer Research (2022)

In the original version of this article (1), there were errors in Fig. 5: in Fig. 5B, an incorrect image was used for the SUNE-1-RAB37 cells transfected with siTIMP2-1, and in Figs. 5D and 5E, the group names were typographically missing for the quantification of macroscopic (Fig. 5D) and microscopic metastatic nodules (Fig. 5E) in the Vector and RAB37 groups. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.
THE "REST IN BED" TREATMENT OF INSANITY.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systolic outward movement of left ventricular apical wall as seen by tagging MR images in patients with apical hypertrophic cardiomyopathy Masaki Tsukamoto, Satoshi Hirasaki, Kazuto Yamamoto, Akiko Matsuo, Hiroyuki Matsui, Takashi Nakamura, Akihiro Azuma, Hiroki Sugihara, Toshiro Kuribayashi, Masao Nakagawa. Kyoto Prefectural Yosanoumi Hospital, kyoto, Japan, Kyoto Prefectural University of Medicine, Kyoto, Japan
Journal: Journal of the American College of Cardiology (2001)
Clinical outcomes of neoadjuvant treatment strategies in localized mismatch repair-deficient rectal cancer.
Authors: Leah C Soderberg, Vanessa Wookey, Jessica L. Mitchell, Jacob A. Jochum, Nguyen H. Tran, Thorvardur Ragnar Halfdanarson, Joleen M. Hubbard, Rondell P. Graham, Kellie Leanne Mathis, Amit Mahipal, Zhaohui Jin
Journal: Journal of Clinical Oncology (2022)

192 Background: Rectal cancer treatment paradigm has been evolving over time. Historically, for locally advanced rectal cancer, standard therapy (ST) consisted of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Recently, total neoadjuvant treatment (TNT) approach that delivers both neoadjuvant chemotherapy (CAPOX or FOLFOX) and chemoradiation (or radiation only) prior to surgery is increasingly being utilized. The prognostic and predictive values of mismatch repair deficient (dMMR) in rectal cancer is not well characterized. Most dMMR patients receive the same treatment as MMR proficient (pMMR) patients although there is limited data that dMMR rectal cancer patients may not have the same level of benefits from neoadjuvant treatment. This retrospective study aims to evaluate the clinicopathological/molecular characteristics, disease response, and clinical outcomes in dMMR localized rectal cancer patients. Methods: A retrospective analysis was conducted on consecutive adult patients with a diagnosis of dMMR rectal cancer who were treated at Mayo Clinic between January 2000 to September 2021. Patients who presented with concurrent primary non-colorectal malignancies were excluded. The distributions of demographics, clinicopathological features, biomarkers, and outcome data were collected. Survival was assessed using Kaplan-Meier curves and Cox models were stratified by treatment arms to determine significance of treatment strategies. Results: Forty-one patients were identified with a median age of 45.3 years. Thirty (73.2%) pts were male. The most common MMR were loss of MSH2 and MSH6 (12/42; 29.3%) followed by loss of MLH1 and PMS2 (10/42; 24.4%) and solitary loss of MSH2 (4/42; 9.8%). The treatment, pathological response, and clinical outcomes are listed in table. With a median follow up of 101 months, only 6 patients (14.3%) died and median overall survival was not reached. Conclusions: Our findings showed dMMR localized rectal cancer responded to both ST and TNT with good clinical outcomes.[Table: see text]
How to examine the oro-naso-laryngo-pharynx for cancer
Authors: J. Conley
Journal: JAMA (1971)

The key to the successful management of any lesion in the area of the head and neck is diagnosis. One of the greatest problems in accomplishing an accurate diagnosis is a cursory, superficial, or incomplete examination. The clinician possesses all of the facilities to inspect, palpate, and smell the various regions in the head and neck in order to create a diagnostic impression. This impression should be substantiated by microscopic documentation before proceeding with a therapeutic program.<sup>26,27</sup> The experience of inspection includes placing the patient in a sitting position which usually affords the best access for examination. Illumination of the deep recesses is accomplished either by the use of a head light or head mirror. The various regions of the scalp, ear, face, skin, oral cavity, neck,<sup>28-30</sup>salivary glands, and thyroid, can be immediately inspected. The regions of the nasal cavity, nasopharynx, oral and hypopharynx, larynx, and ear
Optineurin Guards IFNγ Signaling in Cancer Cells
Authors: Camilla Salvagno, Juan R. Cubillos-Ruiz
Journal: Cancer Discovery (2021)

Abstract Summary: In this issue, Du and colleagues uncover that optineurin functions as a key regulator of IFNγ receptor (IFNGR1) stability in malignant cells. Loss of optineurin in colorectal cancer cells causes IFNGR1 degradation, leading to impaired IFNγ signaling, decreased MHC-I expression, and enhanced ability to evade adaptive immune control. See related article by Du et al., p. 1826.
Insulin Signal Transduction and the IRS Proteins
Authors: M. G. Myers
Journal: The Annual Review of Pharmacology and Toxicology (1996)

Over the past two decades, deadly coronaviruses, with the most recent being the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) 2019 pandemic, have majorly challenged public health. The path for virus invasion into humans and other ...Read More
Pleural Metastasis of Papillary Thyroid Cancer Depicted by 68Ga-FAPI PET/CT
Authors: Yun Chen, Shan Zheng, Jiaying Zhang, Shaobo Yao, Weibing Miao
Journal: Clinical Nuclear Medicine (2022)

Abstract A 43-year-old woman with history of papillary thyroid cancer status post total thyroidectomy and neck dissection and multiple radioiodine therapy developed dyspnea and cough. CT scan of the chest showed left pleural thickening and pleural effusion. The pathology from pleural biopsy demonstrated the metastases from papillary thyroid cancer. 68 Ga–fibroblast activation protein inhibitor PET/CT showed inhomogeneously increased uptake of fibroblast activation protein inhibitor in the thickened pleura.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Authors: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela Motter
Journal: Journal of the National Comprehensive Cancer Network (2022)

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.
Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.
Authors: Jeremy Sharib, Annie Liu, John Creasy, Benjamin Wildman-Tobriner, Hope Elizabeth Uronis, John H. Strickler, David S. Hsu, Sabino Zani, Peter J Allen, Michael Lidsky
Journal: Journal of Clinical Oncology (2022)

120 Background: Hepatic artery infusion (HAI) is a liver directed therapy to treat unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma (ICC). Historically, HAI has only been performed at few specialized centers; however, there is increasing expansion to new centers. We previously reported safety outcomes of our index year of HAI therapy. We now report safety, feasibility, efficacy and oncologic outcomes for an expanded cohort of 62 patients in an established HAI program. Methods: Patients selected for HAI by multidisciplinary review were evaluated for demographics and perioperative outcomes. Objective hepatic response was calculated according to RECIST 1.1. Overall, hepatic and extrahepatic progression-free survival (PFS) were calculated by the Kaplan-Meier method on an intent-to-treat basis. Results: 62 patients were treated with HAI from November 2018-September 2021: 46 for unresectable CRLM, 8 as adjuvant HAI for resected CRLM, and 8 for unresectable ICC. Median age was 54.5 years (range 32-80), 58% were male, and 97% received prior chemotherapy (median 12 cycles, range 0-66). Hepatectomy (18, 29%) and/or colectomy/proctectomy (27, 43.5%) was performed concurrently with pump placement, and 19 (30.6%) were performed robotically. Median operating time was 265 minutes (range 130-526), estimated blood loss was 100 mL (range 22-1000) and length of stay was 5 days (range 1-19). HAI-specific complications occurred in 14% (Table). Floxuridine (FUDR) was initiated in 95% of patients a median of 18.5 days after surgery. Of the 38 patients who received HAI for unresectable CRLM and had measurable disease on imaging, 3- and 6-month hepatic disease control was achieved in 86% (8 partial response [PR], 22 stable disease [SD], 5 progressed [PD]) and 89% (1 complete response, 8 PR, 8 SD, 2 PD), respectively. For patients with at least 3 months follow-up, median PFS, hepatic PFS and extrahepatic PFS were 13 months, 13 months, and 13 months, respectively. Conclusions: HAI can be safely and effectively delivered to well-selected patients with CRLM and ICC. Response rates, disease control and PFS in heavily treated patients with unresectable CRLM comparable to high-volume centers can be achieved at new programs with appropriate expertise. These data support the mission of the newly formed HAI Consortium to critically evaluate efficacy and innovation in HAI therapy through multi-institutional collaboration and contemporary prospective trials.[Table: see text]
Adenosine challenge: A diagnostic test for demonstrating dual atrio ventricular nodal physiology Anoop K. Gupta, Satish C. Toal, Alok Maheshwari, Amit M. Vora, Yash Y. Lokhandwala. KEM Hospital, Mumbai, India, Michigan State University, East Lansing, MI
Journal: Journal of the American College of Cardiology (2001)
Medicolegal aspects of reports on adverse drug reaction
Authors: R. P. Bergen
Journal: JAMA (1965)

With the rapid development of new drugs to treat human illness, the problem of adverse reactions to drugs has increased. In order to assure adequate care, the physician must have available to him the most complete and current information obtainable. To assist in providing this information, the Council on Drugs of the American Medical Association has established the Registry on Adverse Reactions. Physicians and hospitals throughout the country are being urged to report detailed information on instances of adverse effects from drugs to the Registry. Because follow-up of these cases may be required to obtain more information from the physician, it is necessary to identify the cases. A code number is used for this purpose in order to keep the identity of the patient strictly confidential. Obviously certain medicolegal questions arise when any program of this kind is established. Do physicians or hospitals encounter new legal risks or increase their
Amer J of Clinical Nutrition, New York
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Daily aspirin does not guarantee complete inhibition of platelet function and activation during coronary angioplasty: The effect of an additional bolus of high-dose aspirin Jurrien M. ten Berg, Wim B. M. Gerritsen, Fred J. L. M. Haas, Johannes C. Kelder, Freek W. A. Verheugt, Thijs(H) W. M. Plokker. St. Antonius Hospital, Nieuwegein, The Netherlands
Journal: Journal of the American College of Cardiology (2001)